• Mission
  • Team
  • Portfolio
  • News
  • Contact

Eclosion Ventures

~ From discovery to patients ~

GeNeuro and the Karolinska Institutet/Academic Specialist Center of Stockholm announces clinical collaboration

by Eclosion Team | Nov 25, 2019 | Uncategorized

Collaboration follows data from ANGEL-MS extension to Phase 2 MS trial    Aims to address key unmet need of slowing or stopping disease progression   Geneva, Switzerland, November 25, 2019 – 7:30am CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO),...

GeNeuro to Present at 3rd 2019 HERVs & Disease International Workshop on Human Endogenous Retroviruses (HERVs) and Diseases

by Eclosion Team | Oct 31, 2019 | Uncategorized

A must-attend and rapidly growing event with experts around the world: 36 speakers from 10 countries In-depth scientific review of the role played by the HERVs in a broad range of diseases including multiple sclerosis, amyotrophic lateral sclerosis and cancer Focus on...

GeNeuro’s temelimab shows extended neuroprotective effects in relapsing-remitting MS

by Eclosion Team | Sep 16, 2019 | Uncategorized

Further evidence adds to already strong set of positive clinical data Data presented at ECTRIMS 2019 Congress in Stockholm, Sweden Geneva, Switzerland, September 16, 2019 – 7:30 am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company...

GenKyoTex announces positive post-hoc analysis of PBC Phase 2 trial

by Eclosion Team | Jul 25, 2019 | Uncategorized

Setanaxib (GKT831) achieved statistical significance (p=0.02) for primary endpoint with the 400mg BID versus placebo, after correction of nonnormal distribution (outliers) in 400mg OD In advanced patients, setanaxib 400mg BID achieved significant reductions in GGT...

The WHO recognizes NOX inhibitors as new therapeutic class and approves SETANAXIB for GKT831

by Eclosion Team | Jul 22, 2019 | Uncategorized

World Health Organization (WHO) recognized GKT831 as first representative of NOX inhibitor therapeutic class The recommended new stem “naxib” recognizes NOX inhibitors as a new therapeutic class The NOX inhibitor therapeutic class has significant potential in...

Genkyotex Announces FDA Approval of Phase 2 InvestigatorInitiated Trial with GKT831 in IPF

by Eclosion Team | Jul 17, 2019 | Uncategorized

Study expands potential clinical indications for lead compound Trial fully funded via a grant from the United States National Institutes of Health Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX) a biopharmaceutical company and the leader in NOX...
« Older Entries
Next Entries »
Cleantalk Pixel